The CREDENCE trial, the first clinical trial to report the impact of SGLT-2 inhibitors on the kidneys, showed that the risk of renal failure was lower in the canagliflozin group than in the placebo group among patients with T2DM combining chronic kidney disease (CKD) (Perkovic et al., 2019). The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.